With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
Mismatch repair-deficient tumors with many insertion-deletion mutations and enhanced microsatellite instability responded better to anti-PD-1 immunotherapy.
With genomic and proteomic profiles for more than 100 colon cancer cases, researchers identified drug targets, treatment resistance insights, potential cancer drivers, and more.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
The companies will combine their respective technologies to create a biomarker and companion diagnostic development service for pharmaceutical customers.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
